RENAL CELL CARCINOMA

This study tests a new drug called ARRY-614 combined with standard immunotherapies (nivolumab or nivolumab+ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds a safe dose, and the second part checks if the combinat…

This study tests an experimental drug called INBRX-106, given alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced solid tumors (like lung, head and neck, melanoma, stomach, kidney, or bladder cancer) that have stopped responding to standard treatment…

This early-phase study tests whether giving kidney cancer patients a fecal microbiota transplant (FMT) before and during immunotherapy can prevent severe side effects like colitis. About 20 adults with advanced kidney cancer will receive FMT alongside the drugs ipilimumab and niv…

This early-phase study tests a new drug called belzutifan, alone or combined with lenvatinib and pembrolizumab, in Chinese patients with advanced kidney cancer that cannot be removed by surgery. The main goals are to check safety, how the body processes the drugs, and initial sig…

This study tested two drug combinations (lenvatinib plus everolimus or pembrolizumab) against the standard drug sunitinib in people with advanced kidney cancer. The goal was to see if the combinations could slow cancer growth better than sunitinib alone. Over 1,000 participants t…

This study planned to test a material called PuraBond that helps stop bleeding during robotic kidney cancer surgery. It was designed for adults having a partial nephrectomy, where only the tumor is removed. The study was withdrawn before any participants were enrolled, so no resu…

This study tests a freezing technique called cryotherapy to destroy small kidney tumors (up to 5 cm) in 120 adults. The goal is to see if the procedure can completely freeze the tumor with a safe margin and prevent it from coming back. Participants are followed for 5 years to che…

This early-stage study tests a new cancer vaccine (p53MVA) combined with the immunotherapy drug pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The vaccine helps the immune system recognize and attack cancer cells, while pembrolizum…

This early-phase study tests a new drug (APX005M) combined with two existing immunotherapy drugs (nivolumab and ipilimumab) in people with advanced melanoma or kidney cancer who haven't had prior immunotherapy. The main goals are to check safety and find the best dose. About 26 a…

This early-phase study tests whether a new immune cell therapy, called memory-like natural killer (NK) cells, can be safely given to people with advanced kidney or bladder cancers. The treatment involves collecting a patient's own immune cells, boosting them with special proteins…

This study is for people with advanced solid tumors (like lung, bladder, or skin cancer) that have stopped responding to standard immunotherapy drugs called PD-1/PD-L1 inhibitors. Researchers are testing a new combination of immune-boosting drugs to see if they can shrink tumors …

This study looks at how well surgery to remove kidney cancer tumors (including those that have spread) works for controlling the disease. About 86 people with kidney cancer will have the surgery and then be followed to see if they stay cancer-free. The goal is to learn if this ap…

This study tests a personalized approach to treating advanced clear cell kidney cancer by adjusting doses of immunotherapy (pembrolizumab) and a targeted drug (axitinib) based on tumor response. It aims to see if this flexible dosing is feasible and helps control the disease long…

This study tests a drug called 177Lu-PSMA-617, which delivers radiation directly to cancer cells, in 24 people with advanced clear cell kidney cancer that has spread. The goal is to see if it shrinks tumors and how safe it is. Participants must have a specific marker (PSMA) on th…

This early-phase study tests two or three drugs together (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced cancers of the urinary and genital systems that have spread. The main goals are to find the safest dose and understand side effects. About 152 adul…

This early-phase study tests a new drug called AI-061, which combines two immunotherapy agents (anti-PD-1 and anti-CTLA-4) into one treatment. The goal is to find the safest dose and see if it can shrink tumors in people with advanced cancers like melanoma, lung, and ovarian canc…

This study tests a new drug combination (belzutifan plus palbociclib) against belzutifan alone in 60 adults with advanced clear-cell kidney cancer that worsened after at least two prior treatments. The goal is to see if the combination is safe and effective, and to find the best …

This study tests a device called GPX that is used to block blood vessels feeding certain tumors or other problem areas. About 114 adults with conditions like kidney tumors or bone tumors will receive the treatment. The goal is to see if the device is safe and works well at stoppi…

This study tests an experimental drug called entrectinib in people with advanced solid tumors that have certain gene changes (NTRK, ROS1, or ALK). The drug aims to shrink or control the cancer by blocking signals that help it grow. About 534 adults with various cancers, including…

This phase 3 trial tests whether adding the targeted drug cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) helps people with advanced or metastatic kidney cancer live longer without their disease worsening. About 855 participants with intermediate- …

This study tests a new drug combination (BGB-A445 plus tislelizumab) in people with advanced bladder, kidney, or skin cancer that has spread. The goal is to see if the treatment can shrink tumors and how safe it is. About 113 participants will receive the drugs, which aim to boos…

This study tests whether giving immunotherapy before surgery can shrink kidney tumors and reduce the chance of cancer coming back. About 69 adults with a high-risk type of kidney cancer will receive one of three drug combinations before their operation. The goal is to see which t…

This study tests whether giving the drug cabozantinib before surgery can shrink tumors in people with locally advanced kidney cancer. About 22 participants will receive the drug for a short time before their operation. The goal is to see if this approach helps control the disease…

This study tests two new drug combinations for people with advanced kidney cancer that has not been treated before. About 199 participants will receive either a standard treatment or one of two experimental combos that pair immunotherapy with a targeted therapy. The goal is to se…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can help prevent kidney cancer from returning after surgery. About 272 people with intermediate- to high-risk kidney cancer will receive either the vaccine plus immunothe…

This study tests a daily pill called cabozantinib in children and young adults (up to age 30) with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. The drug works by blocking signals that help tumors grow and form blood vessel…

This study tests whether a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) can safely slow the growth of advanced kidney cancer that has spread. About 60 adults with certain types of kidney cancer that cannot be removed by surgery will receive the treatment. …

This study tests giving focused radiation to a blood clot in the main vein caused by kidney cancer, followed by surgery to remove the clot and tumor. It includes 25 newly diagnosed patients. The goal is to see if this approach is safe and helps prevent the cancer from coming back…

This study tests whether adding a new drug (ciforadenant) to two existing immunotherapy drugs (ipilimumab and nivolumab) can better control advanced kidney cancer. About 50 adults with stage IV clear cell kidney cancer who have not had prior treatment will receive the combination…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…

This study tests a combination of two drugs, nivolumab and axitinib, in people with advanced kidney cancer. The first part finds the safest dose, and the second part checks how well the drugs shrink tumors. About 98 participants, both previously treated and untreated, are enrolle…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This early-phase study tests an experimental cell therapy called P-MUC1C-ALLO1 in 180 adults with advanced solid tumors (e.g., breast, ovarian, lung, pancreatic cancers) that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a pro…

This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 par…

This early-phase study tests a new drug called AB248, alone or with another drug (pembrolizumab), in adults with advanced solid tumors (like lung, skin, head/neck, or kidney cancer) that have not been cured by other treatments. The main goal is to check the drug's safety and find…

This study tests a new experimental drug, HFB200603, either alone or combined with another cancer drug (tislelizumab), in adults with advanced solid tumors like kidney, lung, skin, stomach, or colorectal cancer. The goal is to find safe doses and understand side effects. About 83…

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) works better than one drug alone for people with advanced kidney cancer that hasn't been treated before. About 437 participants with intermediate- or poor-risk disease will receive either the co…

This study tests a new two-drug combination (cadonilimab plus axitinib) as a first treatment for people with advanced or spread kidney cancer of rare types. About 37 adults will take the drugs until their disease gets worse or side effects become too severe. The goal is to see if…

This study tests whether giving the drug sunitinib before surgery can help control metastatic kidney cancer. About 50 adults with clear cell renal cell carcinoma who are eligible for kidney removal surgery are participating. Researchers track how long the cancer stays under contr…

This study looks at adults with certain cancers (like lung, breast, kidney, or melanoma) that have spread to the brain. All participants are also receiving immunotherapy. The goal is to see if giving a lower dose of radiation over a few days causes fewer side effects than the sta…

This study looks at whether people with certain cancers prefer getting their pembrolizumab as a shot under the skin (subcutaneous) instead of through an IV. About 147 adults with lung cancer, kidney cancer, or melanoma will try both methods and report which they like better. The …

This study looks back at medical records of 72 American Indian patients treated with immunotherapy for different cancers. Researchers want to see how long these patients lived without their cancer getting worse, their overall survival, and side effects compared to White patients.…

This study looks at four different tools to help people who have had cancer improve their diet and physical activity. About 353 cancer survivors will try these tools to see which ones work best. The goal is to find simple ways to help survivors follow healthy lifestyle guidelines…

This study tests whether a special type of CT scan (DCE-CT) can show if targeted therapy for advanced kidney cancer is working, just days after starting treatment. About 120 adults with metastatic renal cell carcinoma who are already in another treatment study will get these scan…

This study looks at tumor samples from 15 people with kidney or bladder cancer whose cancer came back after immunotherapy. Researchers compare the genes and structure of the original tumor with the new growth to find clues about why the cancer became resistant. The goal is to bet…

This study looks at whether having patients report their side effects through weekly surveys can help doctors better manage treatment for advanced kidney cancer. About 42 adults taking oral chemotherapy pills will answer questions about symptoms like nausea and fatigue. Their car…

This study looks at the bacteria and fungi found in urine and kidney tissue from people with calcium oxalate kidney stones or renal cell carcinoma (a type of kidney cancer), as well as healthy volunteers. The goal is to see if certain microbes are linked to these conditions. Abou…

This study is creating a registry of people with TFE renal cell carcinoma, a rare type of kidney cancer. Researchers will collect medical information, tumor samples, and scans from up to 28 participants. The goal is to better understand the disease and pave the way for more effec…

This study tests a special needle with a tiny tracking device inside, like a mini GPS, to help doctors find hard-to-see tumors during biopsies or ablation procedures. About 3,900 adults with certain cancers or growths will take part. The goal is to see if this tool can place the …

This study explores whether a special PET/CT scan can help doctors see how kidney cancer responds to immunotherapy. About 46 people with advanced kidney cancer will get the scan before surgery or treatment. The goal is to learn if the scan can predict treatment outcomes, not to p…